Press Releases

Date Title
04/04/11
Summary ToggleLithera, Inc. Appoints Thomas Wiggans to Board of Directors Printer Friendly Version SAN DIEGO, April 4, 2011 – Lithera, Inc. announced today the appointment of Thomas G. Wiggans to its Board of Directors. “Lithera is making substantial progress with LIPO-102 by generating positive results with selective, non-ablative localized fat reduction,” said George Mahaffey, President and
03/21/11
Summary ToggleLithera Announces the Appointment of George W. Mahaffey as President and Chief Executive Officer Printer Friendly Version SAN DIEGO, March 21, 2011 – Lithera, Inc. today announced the appointment of George W. Mahaffey as President and Chief Executive Officer. Mr. Mahaffey will also join the Lithera Board of Directors. John D. Dobak, MD, founder and Chief Executive Officer of Lithera since its inception, will remain on
11/03/10
Summary ToggleLithera Reports Positive Clinical Study Results from a Phase IIb Trial for LIPO-102, a Novel Treatment for Localized Fat Reduction Printer Friendly Version SAN DIEGO – November 3, 2010 – Lithera, Inc. today announced positive results from a Phase IIb clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.
10/12/10
Summary ToggleLithera Announces Notice of Allowance for a Key Patent Application for LIPO-102, a Novel Treatment for Localized Fat Reduction Printer Friendly Version SAN DIEGO – October 12, 2010 – Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX)
05/05/10
Summary ToggleLithera Reports Positive Clinical Study Results from a Second Phase IIa Trial for LIPO-102, a Novel Treatment for Localized Fat Reduction Printer Friendly Version SAN DIEGO – May 5, 2010 – Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.
03/09/10
Summary ToggleLithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction Printer Friendly Version SAN DIEGO – March 9, 2010 – Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.
02/23/10
Summary ToggleLithera Obtains Orphan Drug Product Designation for LIPO-102 Printer Friendly Version SAN DIEGO – February 23, 2010 – Lithera, Inc. today announced the receipt of Orphan Drug Product Designation for LIPO-102 for the treatment of symptomatic exophthalmos associated with thyroid-related eye disease, a rare disease affecting less than 200,000 persons in the United States.
02/09/10
Summary ToggleLithera Successfully Completes Phase I Clinical Trial of LIPO-102 Printer Friendly Version SAN DIEGO – February 9, 2010 – Lithera, Inc. today announced the successful completion of a three-part Phase I clinical trial of LIPO-102 being developed for the treatment of thyroid-related (Graves’ Disease) exophthalmos. LIPO-102 is a novel, minimally-invasive, non-ablative approach to localized